WO2022137214A1 - Method to aerosolize nanoparticle formulations - Google Patents
Method to aerosolize nanoparticle formulations Download PDFInfo
- Publication number
- WO2022137214A1 WO2022137214A1 PCT/IB2021/062306 IB2021062306W WO2022137214A1 WO 2022137214 A1 WO2022137214 A1 WO 2022137214A1 IB 2021062306 W IB2021062306 W IB 2021062306W WO 2022137214 A1 WO2022137214 A1 WO 2022137214A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- orifice
- liquid formulation
- nozzle
- nanoparticles
- length
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B17/00—Apparatus for spraying or atomising liquids or other fluent materials, not covered by the preceding groups
- B05B17/04—Apparatus for spraying or atomising liquids or other fluent materials, not covered by the preceding groups operating with special methods
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/0095—Preparation of aerosols
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B12/00—Arrangements for controlling delivery; Arrangements for controlling the spray area
- B05B12/02—Arrangements for controlling delivery; Arrangements for controlling the spray area for controlling time, or sequence, of delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
Definitions
- the present invention relates to a method to aerosolize nanoparticle formulations, including formulations containing proteins, peptides, DNA, RNA, vesicles, liposomes and antibodies.
- Nebulizers generate aerosols by using either compressed air, an ultrasonic power source or a vibrating mesh/membrane to disperse the formulation.
- Soft mist inhalers produce a mist of fine aqueous droplets by collision of microjets at a very high velocity.
- European patent application EP 3.563.894 discloses an example of such a soft mist inhaler, being used to nebulize a non-Newtonian fluid, like in particular a suspension or emulsion or a liposomal fluid that uses nozzles with a small diameter.
- This known nebulizer comprises a fluid pump for pressurizing the fluid to an operational pressure of 5 to 250 Mpa and forcing the pressurized fluid through two mutually inclined flow channels having a hydraulic diameter in the range of 3 to 20 microns. This produces two crossing fluid jets at extreme high velocity that will impinge on one another to produce a mist of fine aqueous droplets. This collision of both fluid jets at high velocity has a significant impact on the fluid and any particles contained therein. It turns out that fragile, delicate nano-particles tend to be damaged under these conditions and in many cases are unlikely to survive the aerolization process.
- International patent application WO 02/13786 A2 discloses a device and method of producing particles out of a stream of a fluid in which a vibrator is used to force the fluid stream into individual droplets.
- the fluid is being charged electrically and the vibrator comprises particularly an ultrasonic piezoelectric transducer that is able to act on the charged fluid emerging from a nozzle channel having a diameter of at least 100 micron.
- This known method and device subjects the fluid to considerable mechanical stress due to the ultrasonic source or vibrating mesh/membrane. Molecules contained in the fluid are exposed to that stress causing shear stress induced degradation of these molecules. Any delicate and fragile molecules are, hence, prone to degradation using this known device and method.
- this spraying mechanism together with the nozzle diameter of at least 100 micron renders this known device only suitable for applications at relative large dimensions. Decreasing the nozzle diameter from 100 micron to 5 micron, for instance, would increase the damage done to any encapsulated compound by factors of magnitude.
- This known method and device hence, have no potential use in a sub-micron range requiring smaller nozzles and causing even more damage to any compounds contained by the fluid due to increasingly large wall shear forces when reducing the nozzle diameter.
- stress-sensitive nanoparticles such as formulations containing complex proteins, peptides, long chain DNA & RNA, large vesicles, liposomes and/or antibodies.
- the present invention provides a method for delivering nanoparticles in an atmosphere, comprising: providing nano-particles having a particle length (A) in a liquid to form a liquid formulation; pressurizing said liquid formulation to a moderate operating pressure (p) to provide a pressurized liquid formulation; and feeding said pressurized liquid formulation through a spray nozzle orifice, having a channel length (L) between an inlet and an outlet of said orifice and an average channel diameter (H) between said inlet and said outlet, to create a liquid stream of said liquid formulation with a velocity; wherein said moderate operating pressure is held below 10 Mpa and said velocity less than 100 m/s; wherein said orifice has a channel length (L) that is shorter than said average channel diameter (H); and wherein said liquid stream is collected at said outlet as a jet of consecutive liquid droplets that each contain at least one nanoparticle of said nanoparticles.
- the method according to the invention is characterized in that said liquid formulation comprises shear stress-sensitive nano-particles taken from a group, containing complex proteins, large biological molecules, long chain DNA & RNA, viruses, large vesicles, liposomes, bacteriophages, and antibodies, wherein said orifice has a channel length (L) that is shorter than half said average channel diameter (H), and preferably wherein said orifice has a channel length (L) that is at most a quarter of said average channel diameter (H).
- said orifice has a channel length (L) that is shorter than half said average channel diameter (H), and preferably wherein said orifice has a channel length (L) that is at most a quarter of said average channel diameter (H).
- said liquid formulation comprises protein and/or antibody molecules, particularly nucleotide compounds like DNA or RNA molecules, with a molecular weight that is larger than 100.000 g/mol.
- said liquid formulation comprises bacteriophages with an average size larger than 20 nanometre.
- said liquid formulation comprises lipid nanoparticles or liposomes, in particular lung surfactants, of which said length is larger than 20 nanometre, wherein particularly said liquid formulation comprises vesicles that have a content comprising nanoparticles taken from a group, containing proteins, biological molecules, DNA, RNA, vaccines, viruses, bacteriophages and antibodies with a molecular weight above 100.000 Da.
- said nozzle orifice has a substantially constant diameter (H) that is between 1 micron and 10 micron.
- said nozzle orifice has an average diameter (H) between 1 micron and 10 micron; and wherein said orifice tapers over at least part of said length from said inlet to said outlet, wherein particularly said nozzle orifice is provided with a positive taper, narrowing from said inlet entrance to said outlet at substantially a tapering between 5° and 45°.
- an inner wall of said nozzle orifice is provided with a hydrophobic slip flow enabling coating.
- the method according to the invention is characterized in that said nanoparticles have a maximum particle length . max before breakage upon elongation; wherein said liquid formulation is subjected to a wall shear rate y wa n [per second] while passing through said spray nozzle orifice; and wherein said liquid formulation is exposed within said spray nozzle orifice to said wall shear rate during a shear time (t) that is less than A max /(A.y wa n) seconds.
- lipid nanoparticles, vesicles, liposomes and other spherical core-shell particles is the ratio A max /A experimentally found to be in a typical small range between 3-5, and on average 4 nearly independent of the particle size above a size of 20 nm.
- Short molecules exhibit a less maximum elongation, but on the other hand are also more stiff and less susceptible to rupture due to the shear forces. Larger molecules (above 500.000 Da) exhibit a larger maximum elongation, but on the other hand are more susceptible to rupture due to the shear forces. These fluid mechanic effects tend to compensate each other for the susceptibility for rupture.
- the ratio A max /A experimentally found to be in a typical range between 2 and 5 for molecules with a molecular weight above 100.000.
- the ratio A max /A is found experimentally to be in a broad range between 2 and 6 for a nano-particle weight above 100.000.
- a preferred embodiment of the method according to the invention is characterized in that the ratio A max /A is set at 4.
- the ratio A max /A experimentally found to be in a typical range between 2 and 6. Also here the said nanoparticle size effects tend to compensate each other with respect to the susceptibility for rupture. However for these highly complex type of nanoparticles, including the compensation effect, the ratio A max /A can best be set at 2 instead of 4.
- the volume averaged degradation is determined by y part with a value always smaller than the wall shear rate y wa n •
- y wall t A max /A ⁇ 2.
- the wall shear rate y wa n is the velocity difference near the wall and perpendicular to the wall divided by the distance to the wall with dimension per second. Shear stress on the nano-particle originates from local velocity gradients over the length of the particle, and the velocity difference over the nanoparticle divided by the size of the nanoparticle, is here named the particle shear rate y part with dimension per second.
- the drag force exerted on the nanoparticle is mainly proportional to the particle shear rate y part , with a value that is substantially less than the wall shear rate v wa n-
- the wall shear rate y wa n and particle shear rate y part near the wall is 8V/H.
- the particle shear rate y part in the middle of the pipe is zero.
- the volume averaged particle shear rate y part in a pipe can therefore vary between about 4V/H, for a long or medium pipe, up to a substantially smaller value, for a short pipe or orifice.
- a relatively short orifice compared to its diameter, is used as it appears more favourable to use relatively short pipes or orifices.
- volume averaged particle shear rate y part is substantially less than the wall shear rate y wa n near the wall, and that a safe condition to maintain the integrity of the nanoparticles is that the shear time is preferably less than A max /(A.y wa n).
- the nanoparticle near the wall is then elongated or deformed with a length A about v wa n times A times A max /(A.y wa ,
- ) A max .
- the aerosolization device should be capable in providing the conditions to impose a wall shear rate y wa n per second during an ultra-short shear time t of less than A max /(A.y wa n) seconds.
- said wall shear rate y wa n is well above 100.000, in particular above 1.000.000 per second.
- said nano-particles comprises macromolecules with a molecular weight that is larger than 100.000 g/mol; and wherein said macromolecules or nano-particles have a ratio A max /A of at least 2, and preferably a ratio A max /A of at least 4.
- Vpart -t ⁇ Ywall -t 8L/H.
- a particular embodiment of the method according to the invention is characterized in that the nanoparticle formulation during aerosolization, producing aerosol droplets with a size of 2-20 micron, through a small nozzle with a diameter H between 1 and 10 micron and a length L smaller than 2 microns, is subject to a wall shear rate Y wa ,i substantially above 1.000.000 per second during an ultra-short shear time t substantially less than 4x10-6 sec (with a maximum nanoparticle elongation A max /A of 4 we get y wa n .t ⁇ 4)
- the condition y wa n -t 8L/H gives then that L ⁇ H/2, or the nozzle length L should not exceed half the diameter H of the nozzle, when aerosolizing liquid formulations comprising shear stress-sensitive nanoparticles, such as proteins, peptides, DNA & RNA, vesicles, liposomes, lipid nanoparticles and antibodies.
- nozzles are used with orifices having a short length as they exhibit plug and slip flow conditions that diminish the nanoparticle shear rate during operation.
- a plug flow condition the particle shear rate away from the nozzle wall is considerably less due to a more even velocity distribution and creating a slip flow condition (e.g. using a hydrophobic nozzle wall), diminishes also the particle shear rate near the nozzle wall.
- nozzles do combine both plug and slip flow at the same time herewith diminishing the volume averaged particle shear rate.
- a further embodiment of the method according to the invention is characterized in that the device produces a jet with an average velocity V coming out of nozzle with a diameter H between 1 and 10 micron and a length L, such that L ⁇ H/2, and that the nozzle pressure is between 10 and 100 bar.
- Increasing the velocity V of the jet above 10 m/s by increasing the nozzle pressure has also been found to diminish the amount of degradation and an optimum operational pressure of about 30-80 bar has been found to diminish the risk of degradation of the nanoparticle formulation.
- the liquid jet coming out of the nozzle entails so much kinetic energy, that the jet immediately disintegrates before it can produce a jet of consecutive droplets that are about twice the diameter of the jet.
- the unwanted turbulence and disintegration of the jet also lead to a strong increase of the volume averaged particle shear rate and increased levels of disruption of the nano-particles.
- a further preferred embodiment of the method according to the invention is, hence, characterized in that a product of a mass density (p) of said fluid, a fluid velocity (V) inside said orifice and said nozzle diameter (H) divided by a viscosity (p) of said fluid, expressed as p.V.H/p, is maintained below 2.500.
- the method according to the invention is characterized in that said nozzle orifice is part of a collection of substantially identical nozzle orifices that extend through a common membrane layer that is supported by a substrate, wherein said substrate has at least one cavity extending to said nozzle orifices of said collection of orifices, and wherein said liquid formulation is delivered at said operating pressure jointly to said cavities to supply said nozzle orifices of said collection of orifices.
- Fig. 1 illustrates the breakup of a macromolecule in a shear flow.
- Fig. 2 illustrates the breakup of a vesicle in a shear flow.
- Fig. 3 illustrates the breakup of a vesicle in a strong shear flow.
- Fig. 4 illustrates the passage of a vesicle through a long pipe.
- Fig. 5 illustrates the passage of a vesicle through an orifice.
- Fig. 6 illustrates the passage of a vesicle through a positively tapered orifice.
- Fig. 7 illustrates the passage of a vesicle through a negatively tapered orifice.
- Fig. 1 illustrates the breakup of a macromolecule in a shear flow.
- Fig. 1A shows a normal globular macromolecule (1) with a gyration diameter A without the presence of a shear flow.
- Fig. IB shows the initial stretching of the globular macromolecule in the presence of a shear flow indicated by arrows (2,3).
- Fig. 1C shows the further stretching to a maximum length . max of the macromolecule and the upper part of the macromolecule moving with a higher velocity starts separating form the lower part with a smaller velocity.
- the upper part (4) and the lower part (5) are only separated by one or two remaining covalent bonds.
- Fig. ID shows the macromolecule after breaking in two parts due to the hydrodynamic shear forces exerted on the upper and lower part of the macromolecule, that cause breaking of the covalent bonds in the middle of macromolecule.
- Macromolecules such as DNA and RNA nucleic acids are frequently used in gene therapy, in particular non-viral gene delivery vectors with messenger RNA (mRNA) and mini-DNA vectors. These macromolecules can range between 100-10.000 nucleotides or base pairs with corresponding contour lengths from 30 nanometre to 3 micron, making them susceptible to shear-induced degradation. In Table 2 below some results are summarized on shear degradation of a number of these vector molecules.
- the passage time t through an untapered orifice is about 50 nanosecond and less degradation is found than in the case of an average velocity of 5 m/s.
- Fig. 2 illustrates the breakup of a vesicle or a liposome in a shear flow.
- Fig. 2A shows a spherical vesicle (11) with a size A without the presence of a shear flow.
- Fig. 2B shows the initial stretching of the vesicle in the presence of a shear flow indicated by arrows (12,13).
- Fig. 2C shows further stretching to a maximum length A max of the vesicle, because the upper part of the vesicle is moving with a higher velocity than the lower part.
- Fig. 2D shows the vesicle after breaking in two parts (14,15) due to the hydrodynamic shear forces exerted on the upper and lower part of the vesicle, that cause breaking in the middle of the vesicle.
- Fig. 3 illustrates the breakup of a vesicle or a liposome in a strong shear flow.
- Fig. 3A shows the vesicle (11) with a size A without the presence of a shear flow.
- Fig. 3B shows the initial stretching of the vesicle in the presence of the shear flow indicated by arrows (12,13).
- Fig. 3C shows further extreme stretching of the vesicle to a maximum length A max , because the upper part of the vesicle is moving with a much higher velocity than the lower part.
- Fig. 3D shows the vesicle after breaking in three parts (14,15,16) due to the large hydrodynamic shear forces exerted on the vesicle, that cause breaking in the vesicle in three parts.
- Fig. 4 illustrates the breakup of a vesicle or a liposome (21) in a long pipe (22) with length L and diameter H.
- the vesicle (21) Before the entrance of the pipe the vesicle (21) is round due to the absence of a large shear flow.
- the vesicle enters the pipe it will be subject to a shear flow (23), and after the stretching stages of the vesicle it breaks in three elongated parts before it exits the pipe. The three parts travel further in the jet and due to the absence of shear the three parts attain their spherical shape.
- Fig. 5 illustrates the travelling of a vesicle or a liposome (21) through an orifice with length L and diameter H.
- the vesicle (21) Before the entrance of the orifice the vesicle (21) is round due to the absence of a large shear flow.
- the vesicle passes the orifice, it will be subject to a shear flow (23), becomes elongated, but will not break.
- the vesicle next enters in the jet part and will attain again its spherical shape.
- Fig. 6 illustrates the travelling of a vesicle or a liposome (21) through a positively tapered orifice with length L and diameter H, exhibiting plug flow.
- the vesicle Before the entrance of the tapered orifice the vesicle is round and due to the small shear in the plug flow it remains mainly spherical. The vesicle subsequently enters in the jet part and attains its spherical shape.
- Fig. 7 illustrates the travelling of a vesicle or a liposome (21) through a negatively tapered orifice with length L and diameter H, also known as a diffuser. Due to the widening, there is a reduction of shear on the nanoparticles in the flow.
- tapering orifices with a wide tapering angle according to the invention may also be chosen to have a total length substantially larger than the most narrow diameter, because the detrimental effect on the integrity of the nanoparticles is the largest in the most narrow part of the tapering orifice with a narrow part length L to narrow diameter H ratio as presented according to the invention.
- Vesicles and liposomes are also frequently used in gene therapy, in particular to promote the delivery of encapsulated RNA and DNA vectors to the lungs. These vesicles can typically range in size between 0.02 and 2 micron, making them potentially susceptible to shear-induced breakage during aerosolization. In Table 3 below some results are summarized on shear degradation of a number of these vesicles.
- a formulation that comprises lipid nanoparticles (LNP) or hybrid nanoparticles with polymers (HNP) with a length or size A larger than 20 nanometre and which LNP's or HNP's having a content comprising other nanoparticles taken from a group, containing proteins, biological molecules, DNA, RNA, mRNA and antibodies.
- LNP lipid nanoparticles
- HNP hybrid nanoparticles with polymers
- tapering orifices with a wide tapering angle according to the invention may also be chosen to have a total length substantially larger than the most narrow diameter, because the detrimental effect on the integrity of the nanoparticles is the largest in the most narrow part of the tapering orifice with a narrow part length L to narrow diameter H ratio as presented according to the invention.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Colloid Chemistry (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202180087564.1A CN116723892A (zh) | 2020-12-24 | 2021-12-24 | 气溶胶化纳米颗粒制剂的方法 |
| EP21835871.1A EP4267292A1 (en) | 2020-12-24 | 2021-12-24 | Method to aerosolize nanoparticle formulations |
| JP2023538845A JP7882853B2 (ja) | 2020-12-24 | 2021-12-24 | ナノ粒子製剤のエアロゾル化方法 |
| US18/269,012 US20240299898A1 (en) | 2020-12-24 | 2021-12-24 | Method to Aerosolize Nanoparticle Formulations |
| BR112023012420A BR112023012420A2 (pt) | 2020-12-24 | 2021-12-24 | Método para aerossolizar formulações de nanopartículas |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2027229A NL2027229B1 (en) | 2020-12-24 | 2020-12-24 | Device and method to aerosolize nanoparticle formulations |
| NL2027229 | 2020-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022137214A1 true WO2022137214A1 (en) | 2022-06-30 |
Family
ID=76159836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2021/062306 Ceased WO2022137214A1 (en) | 2020-12-24 | 2021-12-24 | Method to aerosolize nanoparticle formulations |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240299898A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4267292A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7882853B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN116723892A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023012420A2 (cg-RX-API-DMAC7.html) |
| NL (1) | NL2027229B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022137214A1 (cg-RX-API-DMAC7.html) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002013786A2 (en) | 2000-08-15 | 2002-02-21 | Board Of Trustees Of The University Of Illinois | Method of forming microparticles |
| WO2012024595A2 (en) * | 2010-08-20 | 2012-02-23 | University Of Washington | Circumferential aerosol device for delivering drugs to olfactory epithelium and brain |
| WO2017083464A1 (en) * | 2015-11-12 | 2017-05-18 | Cornell University | Alternating current electrospray manufacturing and products thereof |
| WO2017180151A1 (en) * | 2016-04-15 | 2017-10-19 | Kaer Biotherapeutics Corporation | Aerosolizing nozzle and method of operating such aerosolizing nozzle |
| US20190160232A1 (en) * | 2016-10-11 | 2019-05-30 | Kaer Biotherapeutics Corporation | Apparatus and method for generating and concentrating fine particle aerosols |
| EP3563894A1 (en) | 2018-05-04 | 2019-11-06 | Boehringer Ingelheim International GmbH | Nebulizer and container |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001019528A1 (en) * | 1999-09-15 | 2001-03-22 | Aradigm Corporation | Pore structures for reduced pressure aerosolization |
| GB2375308A (en) * | 2001-05-10 | 2002-11-13 | Cambridge Consultants | Inhalers |
| ES2235642B2 (es) * | 2003-12-18 | 2006-03-01 | Gat Formulation Gmbh | Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos. |
| JP2007038124A (ja) * | 2005-08-02 | 2007-02-15 | Institute Of Physical & Chemical Research | 液体微粒子化ノズル及びそれを用いた装置 |
| US20100179368A1 (en) * | 2008-11-07 | 2010-07-15 | Aries Associates, Inc. | Novel Chemistries, Solutions, and Dispersal Systems for Decontamination of Chemical and Biological Systems |
| BR112013029729A2 (pt) * | 2011-05-23 | 2017-01-24 | Basf Se | controle de emulsões, incluindo emulsões múltiplas |
| WO2013166542A1 (en) * | 2012-05-11 | 2013-11-14 | Monash University | Microfluidic apparatus for the atomisation of a liquid using surface acoustic waves |
| AU2016228941B2 (en) * | 2015-03-11 | 2021-07-08 | University Of South Australia | Drug delivery composition comprising polymer-lipid hybrid microparticles |
| WO2017095219A1 (en) * | 2015-12-04 | 2017-06-08 | Medspray Bv | Spray device and spray nozzle body |
| CN108602080B (zh) * | 2015-12-04 | 2022-06-24 | 美德斯普瑞公司 | 流体喷雾器 |
| US10980954B1 (en) * | 2020-06-30 | 2021-04-20 | ION-Biomimicry | Patient ventilator control using constant flow and breathing triggers |
-
2020
- 2020-12-24 NL NL2027229A patent/NL2027229B1/en active
-
2021
- 2021-12-24 BR BR112023012420A patent/BR112023012420A2/pt unknown
- 2021-12-24 WO PCT/IB2021/062306 patent/WO2022137214A1/en not_active Ceased
- 2021-12-24 EP EP21835871.1A patent/EP4267292A1/en active Pending
- 2021-12-24 JP JP2023538845A patent/JP7882853B2/ja active Active
- 2021-12-24 US US18/269,012 patent/US20240299898A1/en active Pending
- 2021-12-24 CN CN202180087564.1A patent/CN116723892A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002013786A2 (en) | 2000-08-15 | 2002-02-21 | Board Of Trustees Of The University Of Illinois | Method of forming microparticles |
| WO2012024595A2 (en) * | 2010-08-20 | 2012-02-23 | University Of Washington | Circumferential aerosol device for delivering drugs to olfactory epithelium and brain |
| WO2017083464A1 (en) * | 2015-11-12 | 2017-05-18 | Cornell University | Alternating current electrospray manufacturing and products thereof |
| WO2017180151A1 (en) * | 2016-04-15 | 2017-10-19 | Kaer Biotherapeutics Corporation | Aerosolizing nozzle and method of operating such aerosolizing nozzle |
| US20190160232A1 (en) * | 2016-10-11 | 2019-05-30 | Kaer Biotherapeutics Corporation | Apparatus and method for generating and concentrating fine particle aerosols |
| EP3563894A1 (en) | 2018-05-04 | 2019-11-06 | Boehringer Ingelheim International GmbH | Nebulizer and container |
Non-Patent Citations (1)
| Title |
|---|
| EUGENE R ARULMUTHU ET AL: "Studies on aerosol delivery of plasmid DNA using a mesh nebulizer", BIOTECHNOLOGY AND BIOENGINEERING, JOHN WILEY, HOBOKEN, USA, vol. 98, no. 5, 11 May 2007 (2007-05-11), pages 939 - 955, XP071155302, ISSN: 0006-3592, DOI: 10.1002/BIT.21493 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4267292A1 (en) | 2023-11-01 |
| NL2027229B1 (en) | 2022-07-20 |
| US20240299898A1 (en) | 2024-09-12 |
| CN116723892A (zh) | 2023-09-08 |
| JP2024501942A (ja) | 2024-01-17 |
| JP7882853B2 (ja) | 2026-06-30 |
| BR112023012420A2 (pt) | 2023-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Khan et al. | Impact of phospholipids, surfactants and cholesterol selection on the performance of transfersomes vesicles using medical nebulizers for pulmonary drug delivery | |
| JP5850544B2 (ja) | スプレー乾燥装置 | |
| Duong et al. | Scalable, semicontinuous production of micelles encapsulating nanoparticles via electrospray | |
| KR100867392B1 (ko) | 마이크로입자 | |
| US6764720B2 (en) | High mass throughput particle generation using multiple nozzle spraying | |
| AU2010246904B2 (en) | Microfluidic apparatus for the atomisation of a liquid | |
| Wu et al. | Coaxial electrohydrodynamic spraying: a novel one-step technique to prepare oligodeoxynucleotide encapsulated lipoplex nanoparticles | |
| AU1572999A (en) | Device and method for creating dry particles | |
| Lentz et al. | Effect of jet nebulization on DNA: identifying the dominant degradation mechanism and mitigation methods | |
| US7914714B2 (en) | Methods and apparatus using electrostatic atomization to form liquid vesicles | |
| AU2001261625A1 (en) | High mass throughput particle generation using multiple nozzle spraying | |
| CN119136870A (zh) | 鼻喷雾装置和雾化液体制剂的方法 | |
| Lentz et al. | Rationale for the selection of an aerosol delivery system for gene delivery | |
| Anumolu et al. | Fabrication of highly uniform nanoparticles from recombinant silk-elastinlike protein polymers for therapeutic agent delivery | |
| US20240299898A1 (en) | Method to Aerosolize Nanoparticle Formulations | |
| JPH03202137A (ja) | 粉体の表面被覆方法とその装置 | |
| EP2142209B1 (en) | Aerosol dispersions of particles with active pharmaceutical ingredients | |
| Asanuma et al. | Deagglomeration of spray-dried submicron particles by low-power aqueous sonication | |
| JP2024501942A5 (cg-RX-API-DMAC7.html) | ||
| Martin-Banderas et al. | Use of Flow Focusing® technology to produce tobramycin-loaded PLGA microparticles for pulmonary drug delivery | |
| Blynskaya et al. | Perspectives of the development of pharmaceutical nanotechnology | |
| Hervella et al. | Nanocapsules as carriers for the transport and targeted delivery of bioactive molecules | |
| CN114867472B (zh) | 用于基因治疗的金脂质纳米颗粒 | |
| Movahedi et al. | An experimental and numerical study of microfluidic preparation of chitosan nanoparticle | |
| WO2025177008A1 (en) | Spray freeze drying formation of dry powder compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21835871 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 18269012 Country of ref document: US Ref document number: 2023538845 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202180087564.1 Country of ref document: CN |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023012420 Country of ref document: BR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 202327049511 Country of ref document: IN |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2021835871 Country of ref document: EP Effective date: 20230724 |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112023012420 Country of ref document: BR Free format text: APRESENTE A TRADUCAO SIMPLES DA FOLHA DE ROSTO DA CERTIDAO DE DEPOSITO DA PRIORIDADE NL 2027229 DE 24/12/2020 OU DECLARACAO CONTENDO, OBRIGATORIAMENTE, TODOS OS DADOS IDENTIFICADORES DESTA CONFORME O PARAGRAFO UNICO DO ART. 15 DA PORTARIA/INPI/NO 39/2021. A EXIGENCIA DEVE SER RESPONDIDA EM ATE 60 (SESSENTA) DIAS DE SUA PUBLICACAO E DEVE SER REALIZADA POR MEIO DA PETICAO GRU CODIGO DE SERVICO 207. |
|
| ENP | Entry into the national phase |
Ref document number: 112023012420 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230621 |